18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC) Meeting Abstract


Authors: Autio, K. A.; Fox, J. J.; Jia, X.; Heller, G.; Schoder, H.; Humm, J.; Haupt, E. C.; Schneider, C.; Scher, H. I.; Larson, S. M.; Morris, M. J.
Abstract Title: 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC)
Meeting Title: 48th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 30
Issue: 15 Suppl.
Meeting Dates: 2012 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2012-05-20
Language: English
ACCESSION: WOS:000318009802675
PROVIDER: wos
DOI: 10.1200/jco.2012.30.15_suppl.4517
Notes: Meeting Abstract: 4517 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Josef J Fox
    71 Fox
  2. Glenn Heller
    399 Heller
  3. Michael Morris
    577 Morris
  4. Xiaoyu Jia
    46 Jia
  5. Karen Anne Autio
    119 Autio
  6. Heiko Schoder
    543 Schoder
  7. John Laurence Humm
    433 Humm
  8. Steven M Larson
    958 Larson
  9. Howard Scher
    1130 Scher
  10. Eric C Haupt
    8 Haupt